2 reports

THE DRUG CANDIDATE IS A ## MER PEPTIDE ACTS BY TARGETING PROGRAMMED CELL DEATH ## LIGAND ## (PD-L##).

  • Blood Disease
  • Cancer Immunotherapy
  • Cell Therapy
  • Therapy
  • Bristol-Myers Squibb Company

THE DRUG CANDIDATE IS A ## MER PEPTIDE ACTS BY TARGETING PROGRAMMED CELL DEATH ## LIGAND ## (PD-L##).

  • Blood Disease
  • Cancer Immunotherapy
  • Cell Therapy
  • Therapy
  • Bristol-Myers Squibb Company